Drug Profile
Research programme: MCHR1 protein antagonists - Curia
Alternative Names: AMR-MCH-1; AMR-MCH-14; AMR-MCH-18; AMR-MCH-2Latest Information Update: 13 Oct 2021
Price :
$50
*
At a glance
- Originator AMRI
- Class Dihydropyridines; Indazoles; Small molecules
- Mechanism of Action MCHR1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Obesity
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 28 Apr 2016 The MCHR1 protein antagonists programme is available for licensing as of 28 Apr 2016. http://www.amriglobal.com/
- 08 Nov 2011 Discontinued - Preclinical for Obesity in USA (PO)
- 20 Aug 2009 Pharmacodynamics data from a preclinical trial in Obesity presented at the 238th American Chemical Society National Meeting (ACS-2009)